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In this issue of Cancer Cell, Dubois and colleagues report a remodeling of calcium influx in prostate cancer
cells. Prostate cancer cells can undergo an oncogenic switch from a calcium influx pathway capable of
inducing apoptosis involving ORAI1 channels to a pro-proliferative calcium influx pathway involving
ORAI1/3 heteromeric channels.The important role of calciumsignaling in a
variety of processes critical in cancer pro-
gression such as proliferation, apoptosis,
and cellular migration (Hanahan and
Weinberg, 2011) has seen increasing
attention being paid to mechanisms that
regulate intracellular free Ca2+ in cancer
cells. A misconception is that the ubiqui-
tous nature of the calcium signal means
that Ca2+ ions are a simple on/off switch
and that therapies targeting calcium
transport would have major effects on all
cell types and therefore could not repre-
sent an approach for molecularly targeted
therapy. However, there is a suite of Ca2+
channels and pumps that enable cells to
specifically regulate the multiple cellular
processes controlled by Ca2+ ions. Many
of these channels and pumps exhibit
very specific tissue distribution, and their
altered expression are a characterizing
feature of some cancers (Monteith et al.,
2012). The work of Dubois et al. (2014) in
this issue of Cancer Cell adds further
nuances and complexity in how calcium
signaling may be altered in some cancers.
The field of calcium signaling was
revolutionized in 2005 and 2006, when
STIM1 and ORAI1 were identified as the
key components of store operated entry
(Feske et al., 2006; Roos et al., 2005).
This calcium influx mechanism was first
described by Putney in 1986, where
the depletion of intracellular Ca2+ stores
served as a signal for the activation of
Ca2+ influx across the plasma membrane
(Putney, 1986). The proteins ORAI1 and
STIM1 have since been respectively
characterized as the calcium influx
channel and the endoplasmic reticulumCa2+ store sensor important in the refilling
of depleted Ca2+ stores in a variety of cell
types. This ORAI1-mediated Ca2+ influx
pathway has also been linked to various
cancers, including those of the breast,
where silencing of ORAI1 or STIM1 can
reduce the invasion of breast cancer cells
in vitro and reduce the development of
metastasis in vivo (Yang et al., 2009).
In contrast to ORAI1, the roles of its
related isoformsORAI2andORAI3 in store
operated Ca2+ entry, and, indeed calcium
signalingandcellular functionmoregener-
ally are more opaque. In the case of
ORAI3, this has led to ORAI3 being
referred to as the ‘‘exceptional’’ ORAI
channel (Shuttleworth, 2012), with an
identified need to better understand its
activation and roles in calcium homeosta-
sis and physiological/pathophysiological
events. In the context of ORAI3 activation,
ORAI1/3 complexes have been reported
to be activated by arachidonic acid and
have been termed the arachidonic acid-
regulatedcalciumchannel orARCchannel
(Mignen et al., 2008). One of the first indi-
cations for a difference in ORAI3 in cancer
emanated from studies in breast cancer.
Motiani et al. (2010) demonstrated that
store operated Ca2+ entry in estrogen re-
ceptor positive breast cancer cell lines
were sensitive to ORAI3 silencing. In
contrast, this Ca2+ influx pathway was
insensitive to ORAI3 silencing in estrogen
receptor negative breast cancer cell lines,
where classic sensitivity to ORAI1
silencing was evident. The paper by
Dubois et al. (2014) now shows that pros-
tate cancer cells can utilize an ORAI1/3
channel to promote Ca2+ influx indepen-Cancer Cdently of Ca2+ store depletion and that
this channel can be activated by arachi-
donic acid. They provide compelling
evidence for the remodeling of the nature
of calcium influx in prostate cancer pro-
gression, one that bestows enhanced
proliferation and apoptotic resistance.
Using a variety of prostate cancer cell
lines, Dubois et al. (2014) show that
calcium influx activated by Ca2+ store
depletion in prostate cancer cells is sensi-
tive to ORAI1 and STIM1 but not ORAI3
silencing. Silencing of ORAI1, but not the
endoplasmic reticulum Ca2+ sensor
and canonical ORAI1 activator STIM1,
reduces the proliferation of prostate
cancercell lines.Thus,proliferation in these
prostate cancer cells must involve a
STIM1-independent mechanism to acti-
vate ORAI1 and is likely to be independent
of calcium store depletion. The investi-
gators then identified that prostate cancer
cells exhibit Ca2+ influx activated by arach-
idonic acid and that this Ca2+ influx is
reduced by ORAI1 or ORAI3 silencing.
Although similar to the ARC channel, the
insensitivity of this channel to STIM1
silencing in prostate cancer cells suggests
that some aspects of the mechanism for
this Ca2+ influx may be distinct to those
previouslycharacterized forARCchannels.
The importance of ORAI3 in prostate can-
cer growth was also demonstrated in vivo,
with ORAI3 silencing reducing proliferation
and ORAI3 overexpression promoting tu-
mor growth. In support of the important
role of the ORAI1/3 channel (and not just
ORAI3 per se), in vivo growth of prostate
cancer cells with induced overexpression
of ORAI3 was reduced byORAI1 silencing.ell 26, July 14, 2014 ª2014 Elsevier Inc. 1
Oncogenic switch triggers
• Increased ORAI3 expression
• Microenvironment factors
Channel Remodeling
• Reduced ORAI1 channels
• Increased ORAI1/3 channels
Ca2+ influx remodeling
• Reduced store operated Ca2+ entry (ORAI1)
• Increased arachidonic acid-mediated Ca2+ influx (ORAI1/3)
Consequences
• Reduced ORAI1-mediated apoptosis (apopt c resistance)
• Increased prolifera on (arachidonic acid ORAI1/3 va on)
Figure 1. An Oncogenic Switch in Prostate Cancer Progression
Increased ORAI3 expression and/or factors in the tumor microenvironment
increase heteromerization of ORAI1 and ORAI3, altering the nature of calcium
influx, increasing proliferation, and promoting apoptotic resistance.
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implications of the results of
Dubois et al. (2014) is the sug-
gestion that elevated prolifer-
ation rates and apoptotic
resistance in prostate cancer
may be due to alterations in
the relative contribution of
calcium influx mediated by
ORAI1 and ORAI1/3 chan-
nels. They propose that there
is a disequilibrium in prostate
cancer cells, which seesCa2+ influx moving away from store oper-
ated calcium entry (which is important
in the induction of apoptosis in pros-
tate cancer cells) toward an arachidonic
acid-activated pro-proliferative Ca2+
influx pathway. The authors also provide
evidence that this shift toward ORAI1/3-
mediated Ca2+ influx in prostate cancer
cells can be driven by either inherent
upregulation of ORAI3 expression in
some prostate cancer cells or factors in
the tumor microenvironment, arachidonic
acid in this case. The authors refer to
such changes as an oncogenic switch.
This switch and its consequences are
shown in Figure 1 (based on Figure 8 in
Dubois et al., 2014). Their work also
highlights the need for more studies
addressing the role of calcium signaling
in the tumor microenvironment in cancer
progression.2 Cancer Cell 26, July 14, 2014 ª2014 ElseviTheworkofDuboisetal. (2014)of course
leads to manymore questions. What other
tumor environmental factors may cause
such an oncogenic switch, and can other
ion channels contribute to the switching
from proapoptotic to pro-proliferative
Ca2+ influx pathways? Are other cancer
types capable of such remodeling, and
what are the consequences? Are prostate
cancer cells that are undergoing a shift to-
ward ORAI1/3-mediated Ca2+ influx hi-
jacking a calcium influx pathway important
in a physiological or developmental
pathway? If so, which ones, and what will
this mean for future therapies?
If selective pharmacological inhibitors
of ORAI1/3-mediated Ca2+ influx can be
developed, they may offer a unique thera-
peutic strategy to reverse the double-
edge sword of enhanced proliferation
and apoptotic resistance in prostateer Inc.cancer cells. Such agents
mayoffer a newkindofmolec-
ular targeted therapy for this
clinically important cancer.
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